This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Bio-Rad
other brands :
Biogenesis, Serotec, Oxford Biomedical Research, AbD Serotec
product type :
antibody
product name :
GOAT ANTI HUMAN CD156b (C-TERMINAL)
catalog :
AHP1071
quantity :
0.1 mg
price :
433 USD
clonality :
polyclonal
host :
goat
conjugate :
nonconjugated
reactivity :
human, rat, chicken
application :
western blot, ELISA
product information
EntityType :
Polyclonal Antibody
EntityCategory :
Antibodies
Region :
(C-TERMINAL)
ProductCode :
AHP1071
Description :
GOAT ANTI HUMAN CD156b (C-TERMINAL)
Specificity :
CD156b
TargetSpecies :
Human
Host :
Goat
Format :
Purified
Isotypes :
Polyclonal IgG
Applications :
E, WB
ApplicationTypes :
ELISA, Western Blotting
CrossReactivities :
Chicken, Hamster, Rat
Quantity :
0.1 mg
QuantityValue :
0.1
QuantityType :
mg
PriceGBP :
309
PriceEUR :
433
PriceUSD :
433 USD
GOAccessions :
GO:0001666, GO:0001934, GO:0002446, GO:0002467, GO:0004222, GO:0005887, GO:0005138, GO:0005178, GO:0005737, GO:0007173, GO:0007219, GO:0008270, GO:0008284, GO:0042493, GO:0009986, GO:0010820, GO:0015629, GO:0016324, GO:0017124, GO:0030165, GO:0030183, GO:0030307, GO:0030511, GO:0031293, GO:0031659, GO:0032496, GO:0032717, GO:0032722, GO:0033025, GO:0033077, GO:0033627, GO:0035313, GO:0035625, GO:0045121, GO:0048011, GO:0048536, GO:0051088, GO:0055099
GOTerms :
activation of cell growth, activation of cell proliferation, activation of chemokine production, activation of protein amino acid phosphorylation, activation of transforming growth factor beta receptor signaling pathway, B cell development, B lymphocyte differentiation, B-cell differentiation, B-lymphocyte differentiation, cell adhesion mediated by integrin complex, cell associated, cell bound, DHR-domain binding, down regulation of interleukin-8 production, down-regulation of interleukin-8 production, downregulation of interleukin-8 production, drug resistance, drug susceptibility/resistance, EGF receptor signaling pathway, EGF receptor signalling pathway, EGFR signaling pathway, EGFR transactivation by GPCR, EGFR transactivation upon GPCR stimulation, epidermal growth factor receptor signalling pathway, G1/S-specific activation of cyclin-dependent protein kinase activity, G1/S-specific positive regulation of cyclin-dependent protein kinase activity, G1/S-specific stimulation of cyclin-dependent protein kinase activity, G1/S-specific up regulation of cyclin-dependent protein kinase activity, G1/S-specific up-regulation of cyclin-dependent protein kinase activity, G1/S-specific upregulation of cyclin-dependent protein kinase activity, GEM domain, GLGF-domain binding, glycolipid-enriched membrane domain, GO:0009928, GO:0009929, GO:0017035, GO:0030179, GO:0042115, IL-6, inhibition of interleukin-8 production, integrin ligand, interleukin-6 receptor ligand, lipid raft, membrane protein solubilization, metalloendoprotease activity, metalloendoproteinase activity, N signaling pathway, N signalling pathway, negative regulation of IL-8 production, nerve growth factor receptor signalling pathway, NGF receptor signaling pathway, NGF receptor signalling pathway, Notch receptor signaling pathway, Notch receptor signalling pathway, Notch signalling pathway, Notch-receptor signaling pathway, Notch-receptor signalling pathway, positive regulation of cyclin-dependent protein kinase activity during G1/S, positive regulation of protein amino acid phosphorylation, positive regulation of TGFbeta receptor signaling pathway, positive regulation of TGF-beta receptor signaling pathway, positive regulation of transforming growth factor beta receptor signalling pathway, response to endotoxin, response to high density lipoprotein particle stimulus, response to hypoxic stress, response to lowered oxygen tension, response to LPS, stimulation of cell growth, stimulation of cell proliferation, stimulation of chemokine production, stimulation of protein amino acid phosphorylation, stimulation of transforming growth factor beta receptor signaling pathway, T cell development in thymus, thymic T cell differentiation, thymocyte cell differentiation, thymocyte differentiation, up regulation of cell growth, up regulation of cell proliferation, up regulation of chemokine production, up regulation of protein amino acid phosphorylation, up regulation of transforming growth factor beta receptor signaling pathway, upregulation of cell growth, up-regulation of cell growth, upregulation of cell proliferation, up-regulation of cell proliferation, upregulation of chemokine production, up-regulation of chemokine production, upregulation of protein amino acid phosphorylation, up-regulation of protein amino acid phosphorylation, upregulation of transforming growth factor beta receptor signaling pathway, up-regulation of transforming growth factor beta receptor signaling pathway, zinc binding
UniprotAccessions :
P78536
Gene :
ADAM17
GeneID URL :
www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=6868
PublishedSynonyms :
ADAM-17, TACE
EntityFormats :
Purified
UNSPSC :
12352203
ProductForm :
Purified IgG - liquid
PrimarySecondary :
Primary
PriceCHF :
507
PriceSEK :
4316
PriceNOK :
4288
PriceDKK :
3223
company information
Bio-Rad
Endeavour House, Langford Business Park
Langford Lane, Kidlington
OXON, OX5 1GE
antibody_sales_uk@bio-rad.com
www.bio-rad-antibodies.com
1 800 265 7376 (North America)
44 (0)1865 852 700 (Rest of World)
headquarters: UK
Bio-Rad is one of the world's leading antibody manufacturers, offering over 12,000 antibodies and related reagents for a focused range of research areas such as immunology, cancer, veterinary research and cell biology through its antibody experts formerly known as AbD Serotec.
The range includes apoptosis kits, autophagy reagents, CD markers, epitope tag antibodies, immunology antibodies, neuroscience antibodies, and veterinary reagents.
Bio-Rad has an ISO 9001 and ISO 13485 certified production facility in the United Kingdom as well as ISO 9001 certified facilities in Germany and the United States.
Our expertise extends to traditional and recombinant antibody generation and production services. Our custom generation service delivers antibodies in as little as 8 weeks with greater than 90% success. The in vitro technology enables selection of antibodies to challenging targets, long term consistent supply, and provision of the antibody sequence.
At Bio-Rad we are committed to your success when using our antibodies and we focus on providing the technology, products and all the supporting information you need to excel in your research.